Day traders following the bmy stock price point out that average intraday volume has increased by 12%, a possible precursor to larger upward price swings. Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on developing treatments for diseases like cancer, inflammatory, immunologic, cardiovascular, or fibrotic diseases. With a market cap of $95.4 billion, Bristol-Myers’ operations span various countries in the Americas, Europe, and the Indo-Pacific. By Trefis Team , Contributor. Forbes contributors publish independent expert analyses and insights. Building a platform to do the job of 1 million analysts Financial strategists tracking the bmy stock price expect mild appreciation if U.S. interest rates stabilize, as lower borrowing costs historically benefit large-cap pharmaceuticals.